Massimo Libra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5857015/publications.pdf

Version: 2024-02-01

304	17,927	13865 67	17105 122
papers	citations	h-index	g-index

313	313	313	27600
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1263-1284.	4.1	1,858
2	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Frontiers in Pharmacology, 2018, 9, 1300.	3.5	602
3	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation, 2006, 46, 249-279.	2.6	584
4	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging, 2011, 3, 192-222.	3.1	520
5	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget, 2011, 2, 135-164.	1.8	509
6	GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget, 2014, 5, 2881-2911.	1.8	407
7	Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers, 2019, 11, 38.	3.7	378
8	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia, 2008, 22, 686-707.	7.2	337
9	Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). International Journal of Oncology, 2016, 48, 869-885.	3.3	302
10	Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology, 2018, 52, 1071-1080.	3.3	281
11	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	1.8	279
12	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. Oncotarget, 2012, 3, 954-987.	1.8	244
13	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia, 2011, 25, 1080-1094.	7.2	232
14	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget, 2014, 5, 4603-4650.	1.8	231
15	Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia, 2008, 22, 708-722.	7.2	222
16	Multifaceted roles of GSK-3 and Wnt/Î²-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia, 2014, 28, 15-33.	7.2	208
17	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia, 2011, 25, 1064-1079.	7.2	190
18	Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection. International Journal of Molecular Medicine, 2020, 46, 957-964.	4.0	176

#	Article	IF	Citations
19	Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia, 2009, 23, 25-42.	7.2	174
20	PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches. Cell Cycle, 2009, 8, 1352-1358.	2.6	173
21	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging, 2017, 9, 1477-1536.	3.1	168
22	Ageing: from inflammation to cancer. Immunity and Ageing, 2018, 15, 1.	4.2	166
23	Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. Cells, 2019, 8, 863.	4.1	156
24	Current Perspectives in Cancer Immunotherapy. Cancers, 2019, 11, 1472.	3.7	149
25	Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene, 2008, 27, 4086-4095.	5.9	147
26	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. Journal of Cellular Physiology, 2011, 226, 2762-2781.	4.1	147
27	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells, 2020, 9, 1110.	4.1	146
28	Effects of mutations in Wnt/Î²-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activityâ€"Diverse effects on cell growth, metabolism and cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2942-2976.	4.1	137
29	Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development. Aging, 2018, 10, 1000-1014.	3.1	135
30	Akt as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets, 2008, 12, 1139-1165.	3.4	125
31	The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle, 2009, 8, 1367-1372.	2.6	123
32	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Advances in Biological Regulation, 2015, 59, 65-81.	2.3	121
33	SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food and Chemical Toxicology, 2020, 146, 111769.	3.6	117
34	Occupational exposure to pesticides as a possible risk factor for the development of chronic diseases in humans. Molecular Medicine Reports, 2016, 14, 4475-4488.	2.4	116
35	Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vascular Medicine, 2005, 10, 1-6.	1.5	113
36	The tumor microenvironment in hepatocellular carcinoma (Review). International Journal of Oncology, 2012, 40, 1733-47.	3.3	111

#	Article	IF	Citations
37	The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle, 2010, 9, 1781-1791.	2.6	110
38	Current and innovative methods for the diagnosis of COVIDâ€'19 infection (Review). International Journal of Molecular Medicine, 2021, 47, .	4.0	110
39	Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget, 2012, 3, 882-892.	1.8	107
40	Prognostic factors in soft tissue sarcomas: a study of 395 patients. European Journal of Surgical Oncology, 2002, 28, 153-164.	1.0	105
41	Cancer-associated stroke: Pathophysiology, detection and management (Review). International Journal of Oncology, 2019, 54, 779-796.	3.3	104
42	Uterine cervical carcinoma: Role of matrix metalloproteinases (Review). International Journal of Oncology, 2009, 34, 897-903.	3.3	103
43	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Advances in Biological Regulation, 2015, 57, 75-101.	2.3	100
44	Activation of the Osteopontin/Matrix Metalloproteinase-9 Pathway Correlates with Prostate Cancer Progression. Clinical Cancer Research, 2008, 14, 7470-7480.	7.0	99
45	Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer. Frontiers in Pharmacology, 2017, 8, 603.	3.5	96
46	NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. Cell Death and Disease, 2016, 7, e2269-e2269.	6.3	94
47	Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer. Cancers, 2019, 11, 610.	3.7	94
48	The therapeutic potential of mTOR inhibitors in breast cancer. British Journal of Clinical Pharmacology, 2016, 82, 1189-1212.	2.4	93
49	Analysis of BRAF Mutation in Primary and Metastatic Melanoma. Cell Cycle, 2005, 4, 1382-1384.	2.6	91
50	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget, 2014, 5, 1576-1594.	1.8	91
51	Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle, 2008, 7, 1745-1762.	2.6	89
52	The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation. Cancer Research, 2007, 67, 4287-4294.	0.9	87
53	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget, 2017, 8, 14221-14250.	1.8	86
54	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). International Journal of Oncology, 2012, 40, 639-44.	3.3	81

#	Article	IF	Citations
55	Diverse roles of GSK-3: Tumor promoterâ€“tumor suppressor, target in cancer therapy. Advances in Biological Regulation, 2014, 54, 176-196.	2.3	80
56	Occupational exposure to carcinogens: Benzene, pesticides and fibers. Molecular Medicine Reports, 2016, 14, 4467-4474.	2.4	80
57	Immunological effects of occupational exposure to lead. Molecular Medicine Reports, 2017, 15, 3355-3360.	2.4	80
58	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 438-448.	4.1	79
59	Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma. Cells, 2020, 9, 1151.	4.1	78
60	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation, 2007, 47, 64-103.	2.6	77
61	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle, 2011, 10, 3003-3015.	2.6	77
62	Adherence to the Mediterranean diet and nasopharyngeal cancer risk in Italy. Cancer Causes and Control, 2017, 28, 89-95.	1.8	77
63	Cutaneous melanoma and the immunotherapy revolution (Review). International Journal of Oncology, 2020, 57, 609-618.	3.3	75
64	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget, 2016, 7, 72758-72766.	1.8	73
65	Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy. Oncotarget, 2011, 2, 538-550.	1.8	73
66	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. Cancers, 2020, 12, 2237.	3.7	71
67	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia, 2008, 22, 2080-2090.	7.2	70
68	Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. Oral Oncology, 2011, 47, 541-545.	1.5	70
69	NF-Î²B inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma. Oncology Reports, 2017, 37, 737-746.	2.6	70
70	The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease. Oncology Reports, 2019, 42, 911-922.	2.6	70
71	Prognostic significance of deregulated microRNAs in uveal melanomas. Molecular Medicine Reports, 2019, 19, 2599-2610.	2.4	69
72	Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. Journal of Clinical Pathology, 2006, 59, 211-215.	2.0	68

#	Article	IF	Citations
73	Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Molecular Cancer Therapeutics, 2008, 7, 510-520.	4.1	68
74	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. Frontiers in Pharmacology, 2018, 9, 856.	3.5	68
75	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. Aging, 2016, 8, 933-944.	3.1	67
76	Melanoma: Molecular pathogenesis and emerging target therapies (Review). International Journal of Oncology, 2009, 34, 1481-9.	3.3	64
77	Red meat and cancer risk in a network of caseâ€“control studies focusing on cooking practices. Annals of Oncology, 2013, 24, 3107-3112.	1.2	64
78	Serum Extracellular Vesicle-Derived circHIPK3 and circSMARCA5 Are Two Novel Diagnostic Biomarkers for Glioblastoma Multiforme. Pharmaceuticals, 2021, 14, 618.	3.8	64
79	Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget, 2011, 2, 1265-1278.	1.8	61
80	The Effect of Dietary Polyphenols on Vascular Health and Hypertension: Current Evidence and Mechanisms of Action. Nutrients, 2022, 14, 545.	4.1	58
81	The miR-200 family in ovarian cancer. Oncotarget, 2017, 8, 66629-66640.	1.8	56
82	Immune-checkpoint inhibitors from cancer to COVIDâ€‘19: A promising avenue for the treatment of patients with COVIDâ€‘19 (Review). International Journal of Oncology, 2020, 58, 145-157.	3.3	55
83	Solid pseudopapillary tumour of the pancreas. Lancet Oncology, The, 2003, 4, 255-256.	10.7	54
84	Emerging MEK inhibitors. Expert Opinion on Emerging Drugs, 2010, 15, 203-223.	2.4	54
85	Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. PLoS ONE, 2015, 10, e0117420.	2.5	54
86	Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. Oncology Letters, 2016, 11, 1021-1025.	1.8	53
87	Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. Cells, 2019, 8, 1251.	4.1	53
88	Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity. Cancers, 2020, 12, 2555.	3.7	52
89	Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy. Clinical Cancer Research, 2003, 9, 743-8.	7.0	52
90	Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. PLoS ONE, 2016, 11, e0152104.	2.5	50

#	Article	IF	Citations
91	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2013, 5, 707-722.	6.9	49
92	Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. Cell Cycle, 2010, 9, 557-563.	2.6	48
93	Metformin influences drug sensitivity in pancreatic cancer cells. Advances in Biological Regulation, 2018, 68, 13-30.	2.3	45
94	Increased Levels of NF-kB-Dependent Markers in Cancer-Associated Deep Venous Thrombosis. PLoS ONE, 2015, 10, e0132496.	2.5	45
95	A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin. Modern Pathology, 2006, 19, 299-306.	5.5	44
96	Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure. Oncology Reports, 2014, 31, 1079-1082.	2.6	44
97	Identification of novel chemotherapeutic strategies for metastatic uveal melanoma. Scientific Reports, 2017, 7, 44564.	3.3	44
98	Quality of Life in Women Diagnosed with Breast Cancer after a 12-Month Treatment of Lifestyle Modifications. Nutrients, 2021, 13, 136.	4.1	43
99	Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. BMC Cancer, 2015, 15, 720.	2.6	42
100	Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial. PLoS ONE, 2020, 15, e0239803.	2.5	42
101	Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle, 2010, 9, 1629-1638.	2.6	41
102	Dietary Inflammatory Index and Risk of Bladder Cancer in a Large Italian Case-control Study. Urology, 2017, 100, 84-89.	1.0	41
103	Advances in Targeting Signal Transduction Pathways. Oncotarget, 2012, 3, 1505-1521.	1.8	41
104	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. Current Pharmaceutical Design, 2012, 18, 1784-1795.	1.9	39
105	Emerging targeted therapies for melanoma treatment (Review). International Journal of Oncology, 2014, 45, 516-524.	3.3	39
106	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. Advances in Biological Regulation, 2017, 65, 77-88.	2.3	39
107	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
108	Association of Viral Infections With Oral Cavity Lesions: Role of SARS-CoV-2 Infection. Frontiers in Medicine, 2020, 7, 571214.	2.6	39

#	Article	IF	Citations
109	The antitumor properties of a nontoxic, nitric oxideâ€“modified version of saquinavir are independent of Akt. Molecular Cancer Therapeutics, 2009, 8, 1169-1178.	4.1	38
110	microRNAs and thyroid cancer: Biological and clinical significance. International Journal of Molecular Medicine, 2012, 30, 991-999.	4.0	38
111	Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. Infectious Agents and Cancer, 2016, 11, 27.	2.6	38
112	Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence . OncoTargets and Therapy, 2019, Volume 12, 3171-3179.	2.0	38
113	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer: Targets and Therapy, 2017, Volume 8, 259-269.	2.7	37
114	Extrahepatic disorders of HCV infection: A distinct entity of B-cell neoplasia?. International Journal of Oncology, 2010, 36, 1331-40.	3.3	36
115	Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review). Oncology Reports, 2012, 28, 418-428.	2.6	36
116	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. Advances in Biological Regulation, 2017, 63, 32-48.	2.3	36
117	The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy. Frontiers in Medicine, 2019, 6, 172.	2.6	36
118	Detection ofBRAFgene mutation in primary choroidal melanoma tissue. Cancer Biology and Therapy, 2006, 5, 225-227.	3.4	34
119	Characterization of human melanoma cell lines and melanocytes by proteome analysis. Cell Cycle, 2011, 10, 2924-2936.	2.6	34
120	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 71, 172-182.	2.3	34
121	Dietary phytoestrogens and biomarkers of their intake in relation to cancer survival and recurrence: a comprehensive systematic review with meta-analysis. Nutrition Reviews, 2021, 79, 42-65.	5.8	34
122	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. Current Pharmaceutical Design, 2016, 22, 2358-2388.	1.9	34
123	Emerging Raf inhibitors. Expert Opinion on Emerging Drugs, 2009, 14, 633-648.	2.4	33
124	Understanding rituximab function and resistance: implications for tailored therapy. Frontiers in Bioscience - Landmark, 2011, 16, 770.	3.0	33
125	Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. Cytokine, 2012, 59, 294-298.	3.2	33
126	Targeting breast cancer initiating cells: Advances in breast cancer research and therapy. Advances in Biological Regulation, 2014, 56, 81-107.	2.3	32

#	Article	IF	Citations
127	Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease. Angiology, 2016, 67, 870-874.	1.8	32
128	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. Anticancer Research, 2018, 38, 3689-3697.	1.1	32
129	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. Journal of Hepatology, 2008, 49, 170-174.	3.7	31
130	Different pediatric brain tumors are associated with different gene expression profiling. Acta Histochemica, 2015, 117, 477-485.	1.8	31
131	Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial. BMC Cancer, 2017, 17, 69.	2.6	31
132	Mediterranean Diet and Bladder Cancer Risk in Italy. Nutrients, 2018, 10, 1061.	4.1	30
133	Droplet Digital PCR Analysis of Liquid Biopsy Samples Unveils the Diagnostic Role of hsa-miR-133a-3p and hsa-miR-375-3p in Oral Cancer. Biology, 2020, 9, 379.	2.8	30
134	Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation, 2020, 77, 100739.	2.3	30
135	Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. Journal of Pathology, 2005, 206, 87-91.	4.5	29
136	Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle, 2010, 9, 1839-1846.	2.6	29
137	Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 483-489.	4.1	29
138	Novel Insights into Epigenetic Regulation of IL6 Pathway: In Silico Perspective on Inflammation and Cancer Relationship. International Journal of Molecular Sciences, 2021, 22, 10172.	4.1	29
139	Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer, 2004, 4, 11.	2.6	28
140	Absence of t(14;18) chromosome translocation in agricultural workers after short-term exposure to pesticides. Molecular Medicine Reports, 2017, 15, 3379-3382.	2.4	28
141	Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. Cancer Biology and Therapy, 2005, 4, 1192-1194.	3.4	27
142	Absence of BRAF Gene Mutation in Non-Melanoma Skin Tumors. Cell Cycle, 2006, 5, 968-970.	2.6	27
143	IL-6-174 G>C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine, 2013, 62, 64-69.	3.2	27
144	Malignant melanoma in elderly patients: biological, surgical and medical issues. Expert Review of Anticancer Therapy, 2015, 15, 101-108.	2.4	27

#	Article	IF	Citations
145	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation, 2018, 69, 16-34.	2.3	27
146	Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acidâ€“nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide - Biology and Chemistry, 2008, 19, 177-183.	2.7	26
147	FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: a pilot study. Future Oncology, 2015, 11, 35-37.	2.4	26
148	HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology, 2005, 42, 1019-1027.	7.3	25
149	Hepatitis C virus (HCV) infection and lymphoproliferative disorders. Frontiers in Bioscience - Landmark, 2005, 10, 2460.	3.0	25
150	â€˜Genetic profilingâ€™ and ovarian cancer therapy (Review). Molecular Medicine Reports, 2011, 4, 771-7.	2.4	25
151	Breast cancer risk in women treated with augmentation mammoplasty (Review). Oncology Reports, 2012, 28, 3-7.	2.6	25
152	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (Review). Molecular Medicine Reports, 2012, 6, 687-694.	2.4	25
153	Duration and intensity of tobacco smoking and the risk of papillary and non-papillary transitional cell carcinoma of the bladder. Cancer Causes and Control, 2014, 25, 1151-1158.	1.8	25
154	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. Leukemia Research, 2015, 39, 1088-1095.	0.8	25
155	Epigenetic alterations and occupational exposure to benzene, fibers, and heavy metals associated with tumor development. Molecular Medicine Reports, 2017, 15, 3366-3371.	2.4	25
156	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 73, 100633.	2.3	25
157	Long pentraxin 3: A marker of inflammation in untreated psoriatic patients. International Journal of Molecular Medicine, 2006, 18, 415.	4.0	24
158	Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). Molecular Medicine Reports, 2011, 4, 203-8.	2.4	24
159	Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells. Oncology Letters, 2016, 12, 3363-3367.	1.8	24
160	Increased Risk of Nasopharyngeal Carcinoma with Increasing Levels of Diet-Associated Inflammation in an Italian Caseâ€“Control Study. Nutrition and Cancer, 2016, 68, 1123-1130.	2.0	24
161	The dose-response relationship between tobacco smoking and the risk of lymphomas: a case-control study. BMC Cancer, 2017, 17, 421.	2.6	24
162	Fluoro-edenite and carbon nanotubes: The health impact of â€˜asbestos-likeâ€™ fibres. Experimental and Therapeutic Medicine, 2016, 11, 21-27.	1.8	23

#	Article	IF	Citations
163	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cellsâ€"Power of nutraceuticals. Advances in Biological Regulation, 2018, 67, 190-211.	2.3	23
164	Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment. Cancers, 2020, 12, 3636.	3.7	23
165	Adherence to the Mediterranean Diet in Maltese Adults. International Journal of Environmental Research and Public Health, 2021, 18, 10.	2.6	23
166	Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue. Leukemia, 2003, 17, 1433-1436.	7.2	22
167	HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. Tissue Antigens, 2010, 75, 127-135.	1.0	22
168	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle, 2012, 11, 4447-4461.	2.6	22
169	Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs. Current Drug Delivery, 2012, 9, 17-29.	1.6	22
170	Dietary intakes of carotenoids and other nutrients in the risk of nasopharyngeal carcinoma: a caseâ€"control study in Italy. British Journal of Cancer, 2012, 107, 1580-1583.	6.4	22
171	Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling. Brain Sciences, 2019, 9, 221.	2.3	22
172	Dietary inflammatory index and cancer risk in the elderly: A pooled-analysis of Italian case-control studies. Nutrition, 2019, 63-64, 205-210.	2.4	22
173	Post-Mortem Detection of SARS-CoV-2 RNA in Long-Buried Lung Samples. Diagnostics, 2021, 11, 1158.	2.6	22
174	Lack of Hcv Infection in Malignant, Cells Refutes the Hypothesis of a Direct Transforming Action of the Virus in the Pathogenesis of Hcv-Associated B-Cell Nhls. Tumori, 2002, 88, 400-406.	1.1	21
175	Analysis of TIMP-1 Gene Polymorphisms in Italian Sclerodermic Patients. Journal of Clinical Laboratory Analysis, 2006, 20, 173-176.	2.1	21
176	Family history of cancer and the risk of bladder cancer: A caseâ€"control study from Italy. Cancer Epidemiology, 2017, 48, 29-35.	1.9	21
177	Roles of p53, NF-ÎºB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation, 2018, 69, 43-62.	2.3	21
178	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. Advances in Biological Regulation, 2020, 78, 100758.	2.3	21
179	Second Primary Lymphoma or Recurrence: A Dilemma Solved by VDJ Rearrangement Analysis. Leukemia and Lymphoma, 2004, 45, 1539-1543.	1.3	20
180	Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Digestive and Liver Disease, 2007, 39, S65-S71.	0.9	20

#	Article	IF	Citations
181	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation, 2008, 48, 113-135.	2.6	20
182	Raf kinase inhibitor protein (RKIP) and phospho-RKIP expression in melanomas. Acta Histochemica, 2013, 115, 795-802.	1.8	20
183	Associations of dietary carbohydrates, glycaemic index and glycaemic load with risk of bladder cancer: a caseâ€“control study. British Journal of Nutrition, 2017, 118, 722-729.	2.3	20
184	Inflammatory status in patients with chronic renal failure: The role of PTX3 and pro-inflammatory cytokines. International Journal of Molecular Medicine, 2007, 20, 471.	4.0	19
185	Role of the HLA Class II: HCV-Related Disorders. Annals of the New York Academy of Sciences, 2007, 1107, 308-318.	3.8	19
186	GSK-3Î² Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells, 2021, 10, 816.	4.1	19
187	Coffee, Tea, Cola, and Bladder Cancer Risk: Dose and Time Relationships. Urology, 2015, 86, 1179-1184.	1.0	18
188	Food consumption, meat cooking methods and diet diversity and the risk of bladder cancer. Cancer Epidemiology, 2019, 63, 101595.	1.9	18
189	Benefits of using probiotics as adjuvants in anticancer therapy (Review). World Academy of Sciences Journal, 0, , .	0.6	18
190	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). International Journal of Oncology, 2021, 59, .	3.3	17
191	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget, 2017, 8, 76525-76557.	1.8	17
192	Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. Haematologica, 2004, 89, 873-4.	3.5	17
193	Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?. International Journal of Oncology, 2022, 60, .	3.3	17
194	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Supportive Care in Cancer, 2020, 28, 4687-4695.	2.2	16
195	Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncology Reports, 2006, 15, 1305-8.	2.6	16
196	Breast cancer: Molecular basis and therapeutic strategies (Review). Molecular Medicine Reports, 2008, 1, 451-8.	2.4	16
197	Diabetes mellitus and the risk of bladder cancer: an Italian caseâ€“control study. British Journal of Cancer, 2015, 113, 127-130.	6.4	15
198	Computational modeling in melanoma for novel drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 609-621.	5.0	15

#	Article	IF	Citations
199	Dietary water intake and bladder cancer risk: An Italian caseâ€“control study. Cancer Epidemiology, 2016, 45, 151-156.	1.9	15
200	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Tumor Biology, 2016, 37, 9855-9863.	1.8	15
201	Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian caseâ€“control study. Cancer Causes and Control, 2017, 28, 791-799.	1.8	15
202	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging, 2020, 12, 10194-10210.	3.1	15
203	Droplet digital PCR for the detection and monitoring of Legionella pneumophila. International Journal of Molecular Medicine, 2020, 46, 1777-1782.	4.0	15
204	Differentiation between non-Hodgkin's lymphoma recurrence and second primary lymphoma by VDJ rearrangement analysis. British Journal of Haematology, 2002, 118, 809-812.	2.5	14
205	In vitro inhibition of enterobacteria-reactive CD4+CD25â˚ T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. European Journal of Pharmacology, 2008, 586, 313-321.	3.5	14
206	Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Antiâ€Tumour Potency on Prostate Cancer Cells. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 63-69.	2.5	14
207	The risk of HCV infection among health-care workers and its association with extrahepatic manifestations. Molecular Medicine Reports, 2017, 15, 3336-3339.	2.4	14
208	Flavonoids and bladder cancer risk. Cancer Causes and Control, 2019, 30, 527-535.	1.8	14
209	Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. Forum on Immunopathological Diseases and Therapeutics, 2011, 2, 179-188.	0.1	14
210	Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes. Journal of Cellular Physiology, 2017, 232, 1144-1150.	4.1	13
211	Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. Oncotarget, 2012, 3, 1236-1245.	1.8	13
212	Cisplatin may be a Valid Alternative Approach in Ovarian Carcinoma with Carboplatin Hypersensitivity. Report of Three Cases. Tumori, 2003, 89, 311-313.	1.1	12
213	Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. International Journal of Oncology, 2010, 37, 1167-76.	3.3	12
214	Modulation of YY1 and p53 expression by transforming growth factor-Î²3 in prostate cell lines. Cytokine, 2011, 56, 403-410.	3.2	12
215	Total Nut, Tree Nut, and Peanut Consumption and Metabolic Status in Southern Italian Adults. International Journal of Environmental Research and Public Health, 2021, 18, 1847.	2.6	12
216	Expression of Cyclin-Dependent Kinase Inhibitor p27Kip1 in AIDS-Related Diffuse Large-Cell Lymphomas Is Associated with Epstein-Barr Virus-Encoded Latent Membrane Protein 1. American Journal of Pathology, 2002, 161, 163-171.	3.8	11

#	Article	IF	Citations
217	Prevalence of hepatitis C virus infection among health-care workers: A 10-year survey. Molecular Medicine Reports, 2010, 3, 561-4.	2.4	11
218	Metabolic disorders and the risk of nasopharyngeal carcinoma: a caseâ€“control study in Italy. European Journal of Cancer Prevention, 2018, 27, 180-183.	1.3	11
219	Bladder cancer risk in users of selected drugs for cardiovascular disease prevention. European Journal of Cancer Prevention, 2019, 28, 76-80.	1.3	11
220	Association between Nutrient-Based Dietary Patterns and Bladder Cancer in Italy. Nutrients, 2020, 12, 1584.	4.1	11
221	Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases. Oncotarget, 2017, 8, 71528-71535.	1.8	11
222	The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3Kâ€“Akt Pathways. Pharmaceutics, 2022, 14, 590.	4.5	11
223	Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2002, 61, 855-856.	0.9	10
224	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. Free Radical Biology and Medicine, 2010, 48, 1090-1099.	2.9	10
225	Regular aspirin use and nasopharyngeal cancer risk: A case-control study in Italy. Cancer Epidemiology, 2015, 39, 545-547.	1.9	10
226	Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer. Oncology Letters, 2016, 11, 3-8.	1.8	10
227	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation, 2019, 72, 22-40.	2.3	10
228	Nitric Oxide in Hematological Cancers: Partner or Rival?. Antioxidants and Redox Signaling, 2021, 34, 383-401.	5.4	10
229	Processed Meat and Risk of Renal Cell and Bladder Cancers. Nutrition and Cancer, 2018, 70, 418-424.	2.0	9
230	Abilities of Î²-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2020, 75, 100672.	2.3	9
231	A tailored health surveillance program unveils a case of MALT lymphoma in an HCV-positive health-care worker. Oncology Letters, 2013, 5, 651-654.	1.8	8
232	YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. International Journal of Molecular Sciences, 2021, 22, 8481.	4.1	8
233	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. Oncotarget, 2017, 8, 113013-113033.	1.8	8
234	The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. Antioxidants, 2022, 11, 1195.	5.1	8

#	Article	IF	Citations
235	JH6 Gene Usage among HCV-Associated MALT Lymphomas Harboring t(14;18) Translocation. Journal of Immunology, 2005, 174, 3839.1-3839.	0.8	7
236	Analysis of interleukin (IL)-1Î² IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncology Reports, 2006, 15, 1305.	2.6	7
237	Dehydroxymethylepoxyquinomicin, a novel nuclear factorâ€ºB inhibitor, prevents inflammatory injury induced by interferonâ€³ and histamine in NCTCâ€ƒ2544 keratinocytes. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 679-683.	1.9	7
238	Low levels of inflammation and the absence of subclinical atherosclerosis in rheumatoid arthritis. Molecular Medicine Reports, 2016, 13, 3521-3524.	2.4	7
239	Association between dietary inflammatory index and Hodgkin's lymphoma in an Italian case-control study. Nutrition, 2018, 53, 43-48.	2.4	7
240	Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 6446.	4.1	7
241	Analysis of hepatitis C virus infection among health-care workers: an observational study. Minerva Gastroenterologica E Dietologica, 2005, 51, 255-9.	2.2	7
242	Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution. Tumori, 2003, 89, 400-404.	1.1	6
243	Breast cancer: Molecular basis and therapeutic strategies (Review). Molecular Medicine Reports, 0, , .	2.4	6
244	Dehydroxymethylepoxyquinomicin Inhibits Expression and Production of Inflammatory Mediators in Interleukin-1Î²-induced Human Chondrocytes. Cellular Physiology and Biochemistry, 2010, 25, 543-550.	1.6	6
245	EpiMethEx: a tool for large-scale integrated analysis in methylation hotspots linked to genetic regulation. BMC Bioinformatics, 2019, 19, 385.	2.6	6
246	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Advances in Biological Regulation, 2021, 79, 100780.	2.3	6
247	Polyphenol-Rich and Alcoholic Beverages and Metabolic Status in Adults Living in Sicily, Southern Italy. Foods, 2021, 10, 383.	4.3	6
248	Co-Occurrence of Interleukin-6 Receptor Asp358Ala Variant and High Plasma Levels of IL-6: An Evidence of IL-6 Trans-Signaling Activation in Deep Vein Thrombosis (DVT) Patients. Biomolecules, 2022, 12, 681.	4.0	6
249	Oral Etoposide in Elderly Patients with Advanced Non Small Cell Lung Cancer: A Clinical and Pharmacological Study. Journal of Chemotherapy, 2006, 18, 188-191.	1.5	5
250	Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST. International Journal of Colorectal Disease, 2014, 29, 639-640.	2.2	5
251	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). Molecular Medicine Reports, 2008, 1, 139-60.	2.4	5
252	Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer. Cancers, 2022, 14, 922.	3.7	5

#	Article	IF	Citations
253	Bovine seminal ribonuclease is cytotoxic for both malignant and normal telomerase-positive cells. International Journal of Oncology, 2005, 27, 1071.	3.3	4
254	Phase II study of the antiretroviral activity and safety of the glucocorticoid receptor antagonist mifepristone in HIV-1-infected patients. International Journal of Molecular Medicine, 2011, 28, 437-42.	4.0	4
255	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Advances in Biological Regulation, 2021, , 100840.	2.3	4
256	Bâ€¢cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Nonâ€Hodgkin's Lymphoma. Hematological Oncology, 2022, , .	1.7	4
257	Mineral fiber-mediated activation of phosphoinositide-specific phospholipase c in human bronchoalveolar carcinoma-derived alveolar epithelial A549 cells. International Journal of Oncology, 1992, 34, 371.	3.3	3
258	Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. International Journal of Oncology, 2005, 26, 945.	3.3	3
259	Gene expression in mouse spermatogenesis during ontogenesis. International Journal of Molecular Medicine, 2006, 17, 523.	4.0	3
260	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2014, 6, 295-295.	6.9	3
261	Molecular analysis of the APC gene in Sicilian patients with familial adenomatous polyposis (F.A.P.). International Journal of Surgery, 2014, 12, S125-S129.	2.7	3
262	Dietary Inflammatory Index in Ageing and Longevity. , 2019, , 71-86.		3
263	Interaction between matrix metalloproteinase-9 (MMP-9) and neutrophil gelatinase-associated lipocalin (NGAL): A recent evolutionary event in primates. Developmental and Comparative Immunology, 2021, 116, 103933.	2.3	3
264	Prognostic Value of the Immunohistochemical Expression of Serine and Arginine-Rich Splicing Factor 1 (SRSF1) in Uveal Melanoma: A Clinico-Pathological and Immunohistochemical Study on a Series of 85 Cases. Applied Sciences (Switzerland), 2021, 11, 7874.	2.5	3
265	Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. International Journal of Oncology, 2005, 26, 945-50.	3.3	3
266	Chronic Pesticide Exposure in Farm Workers Is Associated with the Epigenetic Modulation of hsa-miR-199a-5p. International Journal of Environmental Research and Public Health, 2022, 19, 7018.	2.6	3
267	Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent. International Journal of Molecular Medicine, 2006, 17, 539.	4.0	2
268	Reply:. Hepatology, 2006, 43, 1167-1168.	7.3	2
269	New Perspectives in HCV Therapy: Entry Inhibitors. Recent Patents on Anti-infective Drug Discovery, 2010, 5, 181-194.	0.8	2
270	Overexpression of the Transcription Factor Yin Yang 1 in Non-Hodgkin Lymphoma is associated with Chemo-Immune Resistance. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S119-S120.	0.4	2

#	Article	IF	Citations
271	Quantitative evaluation of partial deletions of the DAZ gene cluster. International Journal of Molecular Medicine, 0, , .	4.0	2
272	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
273	Risk analysis of colorectal cancer in women with endometrial carcinoma. Molecular Medicine Reports, 0, , .	2.4	2
274	Expression of ornithine decarboxylase gene in elderly human monocytes. Archives of Gerontology and Geriatrics, 1994, 18, 141-147.	3.0	1
275	All trans retinoic acid sensitizes colon cancer cells to hyperthermia cytotoxic effects. International Journal of Oncology, 2003, 23, 181.	3.3	1
276	D1S80 VNTR locus genotypes in a population of Southeastern Sicily: Distribution and genetic disequilibrium. American Journal of Human Biology, 2004, 16, 91-94.	1.6	1
277	Two targets are better than one, Promising combination therapy to treat breast cancer. Cancer Biology and Therapy, 2005, 4, 1190-1191.	3.4	1
278	An Italian multicenter controlled study of HCV-related malignancies: Role of the HLA class II. Digestive and Liver Disease, 2006, 38, S30.	0.9	1
279	BRAF and RKIP aberrations in actinic keratosis and non-melanoma skin cancers. Cell Cycle, 2009, 8, 1305-1307.	2.6	1
280	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
281	Molecular screening in Sicilian families with hereditary non-poliposis colorectal cancer (H.N.P.C.C.) syndrome: Identification of a novel mutation in MSH2 gene. International Journal of Surgery, 2014, 12, S120-S124.	2.7	1
282	S100A7/Ran-binding protein 9 coevolution in mammals. Immunogenetics, 2020, 72, 155-164.	2.4	1
283	Computational Evaluation of Yin Yang 1 Transcript Levels in the Spectrum of B-cell Neoplasia. Forum on Immunopathological Diseases and Therapeutics, 2010, 1, 115-125.	0.1	1
284	Rationale for Targeting of YY1 in Drug-resistant Leukemias. Forum on Immunopathological Diseases and Therapeutics, 2010, 1, 65-79.	0.1	1
285	Long term follow up of 50 patients with metastatic renal cell carcinoma treated with high dose i.v. interleukin. 2. European Journal of Cancer, 1999, 35, S358.	2.8	0
286	Carboplatin in Elderly Patients. Tumori, 2002, 88, S35-S36.	1.1	0
287	Cancer risk evaluation: Preliminary analysis of inflammatory biomarkers in farmers exposed to zoonotic agents. International Journal of Infectious Diseases, 2014, 21, 185.	3.3	0
288	Notch4 and MHC class II polymorphisms contribute to HCV-related benign and malignant lymphoproliferative diseases. Digestive and Liver Disease, 2015, 47, e14.	0.9	0

#	Article	IF	Citations
289	P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases. Journal of Hepatology, 2015, 62, S611.	3.7	0
290	Contribution of Immunohistochemistry in Revealing S100A7/JAB1 Colocalization in Psoriatic Epidermal Keratinocyte. Methods in Molecular Biology, 2019, 2109, 67-74.	0.9	0
291	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Signaling and p53 Pathways on Apoptosis, Drug Resistance and Therapeutic Sensitivity of Early Hematopoietic Precursor Cells. Blood, 2008, 112, 503-503.	1.4	0
292	Clinical Significance of YY1 Overexpression in Human Hematopoietic Malignancies. Forum on Immunopathological Diseases and Therapeutics, 2010, 1, 127-139.	0.1	0
293	COMMENTARY. Diagnostic and Prognostic roles of YY1. Forum on Immunopathological Diseases and Therapeutics, 2010, 1, 153-154.	0.1	0
294	Abstract 5263: Osteopontin/matrixmetalloproteinasis pathway activation in head and neck cancer. , 2011, , .		0
295	Abstract 332: B-Raf mutations are associated with a worse outcome in ovarian cancer. , 2011, , .		0
296	Molecular-Targeted Therapy for Melanoma. , 2012, , 265-279.		0
297	Abstract 4197: Discovering FUS-CHOP targets: A Chip-Seq approach. , 2012, , .		0
298	Abstract 4074: Transcription factors involved in the genesis and progression of cancer differently modulated by transforming growth factor-beta3 (TGF-Beta3) in prostate cell lines.. , 2013, , .		0
299	Abstract 4304: MMP-9 as a marker of response to treatment with B-Raf inhibitors in cutaneous melanoma. , 2015, , .		0
300	Yin Yang 1 (YY1) Acting Primarily As an Oncogene and Rarely As a Tumor Suppressor in Distinct Hematological Malignancies: Prognostic and Therapeutic Implications. Blood, 2016, 128, 5122-5122.	1.4	0
301	Abstract 5305: DNA methylation and gene expression in melanoma: A large-scale integrated analysis. , 2018, , .		0
302	Abstract 4836: Diagnostic and prognostic significance of microRNA modulation in oral cancer. , 2020, , .		0
303	Abstract 4687: Oncogenic role of the transcription factor YY1 and its target Survivin in non-Hodgkin's lymphoma. , 2020, , .		0
304	Abstract 2400: Strong biological bias for ALK intron 19 breakpoints in NSCLC. , 2020, , .		0